CDC's Advisory Committee recommends Shingrix over Zostavax for prevention of shingles
Hot on the heels of Canadian and US marketing approval of its shingles vaccine Shingrix, UK pharma major GlaxoSmithKline (LSE: GSK) late yesterday received a follow-on boost for its product with a US recommendation as the preferred shingles vaccine from the committee responsible for vaccination policy in the USA.
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of three recommendations for the use of Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles (herpes zoster):
- Shingrix is recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged 50 years and older.
- Shingrix is recommended for the prevention of herpes zoster and related complications for immunocompetent adults who previously received zoster vaccine live (Zostavax), the established treatment from US pharma giant Merck & Co (NYSE: MRK).
- Shingrix) is preferred over Zostavax for the prevention of herpes zoster and related complications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze